Of note, among these genes were critical regulators of cell cycle progression (MYC, MYB, MYCBP1, CHEK1), transcription factors (RUNX1, NFYC, NFIB, HIF1A, MEIS2), epigenetic modifiers (DNMT1, DNMT3B, TET3, BRD4, SMARCA4, INO80C) as well as established JAK-signaling targets and mediators of MPN-progression and persistence under JAK inhibitor treatment (YBX1, DUSP6, PIM1, ASXL1, BRD4) [27–31]. Here, ASXL1 is linked to myeloproliferative disorder.